期刊文献+

CA125及CA724对晚期肺癌GP方案化疗疗效的预测价值 被引量:15

Prognostic value of CA125 and CA724 for GP chemotherapy in advanced non-small cell lung cancer
下载PDF
导出
摘要 目的探讨血清肿瘤标志物CA125、CA724及CYFRA21-1对晚期非小细胞肺癌化疗疗效的预测价值。方法选取42例经病理证实的初治晚期非小细胞肺癌患者,予GP方案(泽菲+顺铂)一线化疗,于治疗开始前及化疗两周期后抽取患者外周静脉血,采用放射免疫法检测患者血清CA125、CA724及CYFRA21-1的浓度。结果血清CA125水平在稳定组和进展组患者化疗前后的差异有统计学意义(P<0.05);CA724在进展组患者的表达明显高于稳定组(P<0.05);稳定组和进展组及两组化疗前后均未见CYFRA21-1浓度的变化。结论晚期非小细胞肺癌患者血清CA125的变化与GP方案化疗反应有关,CA724的浓度可作为化疗疗效的预测指标。 Objective To determine the prognostic value of serum tumor marker CA125、CA724及CYFRA21-1 for GP chemotherapy in patients with advanced non-small cell lung cancer.Methods forty-two advanced non-small cell lung cancer patients without prior therapy were eligible for this study,and were treated with GP(gemcitabine+cisplain).Blood sample were obtained before the chemotherapy and after two cycles.The expression of CA125、CA724及CYFRA21-1 in serum were examined by radioimmunoassay.Results The level of CA125 decreased significantly in the stable group and increased in the progressive group(P〈0.05);The different expression of CA724 were observed in the stable group and progressive group(P〈0.05);There were no significant change of the level of CYFRA21-1 between the two groups.Conclusion The change of CA125 may be used for the prediction of clinical reaction in advanced NSCLC patients treated with GP,and the level of CA724 correlates with the clinical reaction.
出处 《临床肺科杂志》 2011年第2期232-233,共2页 Journal of Clinical Pulmonary Medicine
关键词 非小细胞肺癌 泽菲(吉西他滨) 肿瘤标志物 non-small cell lung cancer gemcitabine tumor marker
  • 相关文献

参考文献5

  • 1Schiller JH, Hatting TD, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [ J ]. N Engl J Med,2002,346(2) :92 -98.
  • 2Linn W, Volkmar M, Christine E, et al. Serum carbonic anhydrase IX during first-line therapy of ovarian cancer[ J ]. Gynecologic Oncology,2010,117 : 183 - 188.
  • 3EL-Nabi, E. A. A, EL-Din Gornaa, N. E, EL-Karim Abo Zeid, A. A, et al. Evaluation of Cyfra21-1 as diagnostic tool in lung cancer[ J]. Journal of Applied Sciences Resea-rch ,2009,5 (9) :1195 -1201.
  • 4钱晓萍,刘宝瑞,刘新姿,胡文静,王立峰,杨阳.非小细胞肺癌血清VEGF与CA125 CEA Cyfra21-1的相关性及临床意义[J].中国肿瘤临床,2009,36(2):92-96. 被引量:19
  • 5叶江枫,解立新,陈勇,杜永红.血清肿瘤标志物与肺癌的关系[J].临床肺科杂志,2008,13(7):832-834. 被引量:18

二级参考文献18

  • 1Muley T, Fetz TH, Dienemann H, et al. Tumor volume and tumor marker index based on CYERA 21--1 and CEA are strong prognostic factors in operated early stage NSCLC[J]. Lung Cancer, 2008, 60(3): 408---415.
  • 2Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer[J]. Lung, 2005, 183(1): 29--42.
  • 3Jiang X, ZhouJH, Deng ZH, et al. Expression and significance of Notchl,Jaggedl and VEGF in human non--small cell lung cancer[J]. Zhong Nan Da Xue Xue Ban Yi Xue Ban[J]. 2007, 32(6): 1031-1036.
  • 4Tas F, Duranyildiz D, Oguz H, et al. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non--small cell lung cancer[J]. Cancer Invest, 2006, 24(6): 576---580.
  • 5Kim HS, Park NH, Chung HH, et al. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer[J]. Onkologie, 2008, 31 (6) : 315-320.
  • 6Chiu CH, Shih YN, Tsai CM, et al. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefifinib[J]. Lung Cancer, 2007, 57(2): 213-221.
  • 7KulpaJ, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer pafients[J]. Clin Chem, 2002, 48(11): 1931-1937.
  • 8Tamura M, Ohta Y, Nakamura H, et al. Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non--small cell lung cancer[]]. Int J Biol Markers, 2002, 17(4): 275-279.
  • 9Salgia R, Harpole D, Hemdon JE, et al. Role of serum tumor markers CA125 and CEA in non-small cell lung cancer. Anticancer RES,2001, 21 (2B) :1241 - 1246.
  • 10Sawabata N, Ohta M, Takeda S, et al. Serum carcinoembryonic anti- gen level in surgically resected clinical stage Ⅰ patients with non-small cell lung cancer. Ann Thorac Surg. 2002 ;74( 1 ) :174 -179.

共引文献35

同被引文献143

引证文献15

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部